Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8567-8578

  Zhang, Mingjun ^a,b   He, Jin ^a   Liu, Zhiqiang ^a   Lu, Yong ^a,b   Zheng, Yuhuan ^a,b   Li, Haiyan ^a,b   Xu, Jingda ^a   Liu, Huan ^a   Qian, Jianfei ^a,b   Orlowski, Robert Z ^a   Kwak, Larry W ^a   Yi, Qing ^a,b   Yang, Jing ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti 2M monoclonal antibody; Autophagy; Bortezomib; Multiple myeloma; NF p65

Indexed keywords

BECLIN 1; BETA 2 MICROGLOBULIN; BETA 2 MICROGLOBULIN MONOCLONAL ANTIBODY; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BACTERIAL RNA; BECN1 PROTEIN, HUMAN; LAMP1 PROTEIN, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAP1LC3B PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; RELA PROTEIN, HUMAN; RNA I; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; IMMUNOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BECLIN-1; BETA 2-MICROGLOBULIN; BORTEZOMIB; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA, BACTERIAL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928736336     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3251     Document Type: Article

References (46)

1. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998; 92:2908-2913.
2. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM. A unique threedimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008; 112:2935-2945.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351:1860-1873.
4. Cao B, Li J, Mao X. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des. 2013; 19:3190-3200.
5. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011; 11:239-253.
6. Rubinstein AD, Kimchi A. Life in the balance-a mechanistic view of the crosstalk between autophagy and apoptosis. J Cell Sci. 2012; 125:5259-5268.
7. Gordy C, He YW. The crosstalk between autophagy and apoptosis: where does this lead? Protein Cell. 2012; 3:17-27.
8. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010; 29:1717-1719.
9. Rzymski T, Milani M, Singleton DC, Harris AL. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle. 2009; 8:3838-3847.
10. Selimovic D, Porzig BB, El-Khattouti A, Badura HE, Ahmad M, Ghanjati F, Santourlidis S, Haikel Y, Hassan M. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013; 25:308-318.
11. Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PloS One. 2012; 7:e32584.
12. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005; 65:5898-5906.
13. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005; 65:11712-11720.
14. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol. 2002; 21:867-873.
15. Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, Goto T, Matsumoto T. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 1999; 93:3922-3930.
16. Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012; 119:2074-2082.
17. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007; 13:5556s-5563s.
18. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012; 26:2538-2545.
19. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood. 2006; 108:1346-1352.
20. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008; 112:1329-1337.
21. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011; 34:409-418.
22. Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004; 64:4629-4636.
23. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dalken B, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138- positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009; 15:4028-4037.
24. Bjorkman PJ, Burmeister WP. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Curr Opin Struct Biol. 1994; 4:852-856.
25. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006; 10:295-307.
26. Zhang M, Qian J, Lan Y, Lu Y, Li H, Hong B, Zheng Y, He J, Yang J, Yi Q. Anti-beta(2)M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer. 2014; 135:1132-1141.
27. Yang J, Cao Y, Hong S, Li H, Qian J, Kwak LW, Yi Q. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009; 15:951-959.
28. Sekimoto E, Ozaki S, Ohshima T, Shibata H, Hashimoto T, Abe M, Kimura N, Hattori K, Kawai S, Kinoshita Y, Yamada-Okabe H, Tsuchiya M, Matsumoto T. A singlechain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res. 2007; 67:1184-1192.
29. Nomura T, Huang WC, Seo S, Zhau HE, Mimata H, Chung LW. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol. 2007; 178:292-300.
30. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC, Chung LW. beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006; 66:9108-9116.
31. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012; 120:3260-3270.
32. Driscoll JJ, Chowdhury RD. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications. Cancer Lett. 2012; 325:147-154.
33. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008; 6:1356-1364.
34. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008; 7:40.
35. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic antimyeloma activity with dexamethasone. J Mol Med. 2012; 90:695-706.
36. Suzuki K. Current therapeutic strategy for multiple myeloma. Jap J Clin Oncol. 2013; 43:116-124.
37. Chou T. Multiple myeloma: recent progress in diagnosis and treatment. J Clin Exp Hematopathol. 2012; 52:149-159.
38. Romano A, Conticello C, Di Raimondo F. Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy. 2013; 5:327-352.
39. Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012; 7:258-266.
40. Allegra A, Penna G, Alonci A, Russo S, Greve B, Innao V, Minardi V, Musolino C. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013; 90:441-468.
41. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009; 114:1046-1052.
42. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci U S A. 2010; 107:13069-13074.
43. Copetti T, Demarchi F, Schneider C. p6/RelA binds and activates the beclin 1 promoter. Autophagy. 2009; 5:858-859.
44. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone- induced myeloma cell death. Blood. 1994; 84:3063-3070.
45. Huang CJ, Bi EG, Hu Y, Deng WW, Tian ZG, Dong C, Hu YJ, Sun B. A novel NF-kappa B binding site controls human granzyme B gene transcription. J Immunol. 2006; 176:4173-4181.
46. Chen S, Zhang M, Ma H, Saiyin H, Shen S, Xi J, Wan B, Yu L. Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance. Cancer Chemother Pharmacol. 2008; 61:459-469.